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Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leukemia.
By analyzing minimal residual disease (MRD) under the levels of CCR, we tried to assess the molecular
response after imatinib therapy. By using real-time quantitative reverse transcriptase-polymerase chain reac-
tion (Q-RT-PCR), MRD was evaluated in 23 patients (3 in cytogenetic relapse, 6 in chronic phase, 9 in
accelerated phase, and 5 in blast crisis) who were treated with standard-dose imatinib for relapsed chronic
myelogenous leukemia after allogeneic stem cell transplantation. With a median therapy time of 399 days
(range, 35-817 days), 19 (83%) patients achieved a CCR. Meanwhile, 11 (58%) of them achieved a molecular
remission (MR), which was associated with improved survival. The Q-RT-PCR data were compared according
to the best response (MR, n  11; CCR, n  8) in the patients achieving a CCR. The BCR-ABL/ABL ratios
were similar in 2 groups at 3 months but were significantly different at 6 months (median, 0.0000012 for MR
and 0.00022 for CCR; P  .003). The probability of a subsequent MR was significantly higher in patients with
a lower BCR-ABL/ABL ratio at 6 months (100% for <0.0001 versus 33% for >0.0001; P  .006) or a greater
reduction in the level between 3 and 6 months (log-reduction >1.0;, 100%; <1.0, 17%; P  .003). Q-RT-PCR
is a reliable method for monitoring MRD: the early trends in the BCR-ABL/ABL ratio may be clinically useful
in discriminating patients who will achieve an MR from those who will remain in CCR.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Allogeneic stem cell transplantation (SCT) is the
nly curative treatment for chronic myelogenous leu-
emia (CML), and 40% to 80% of these patients
emain disease free for more than 5 years after SCT
1]. CML recurrence, which occurs in approximately
0% to 30% of patients who undergo transplantation
n the ﬁrst chronic phase (CP) and who receive non–T
ell–depleted marrow [2], remains a major cause of
18reatment failure. Donor lymphocyte infusion (DLI)
as been the treatment of choice for relapsed CML
nd results in complete remission in up to 75% of
ases and in durable remission with a rate of almost
0% at 2 to 3 years [3,4]. However, it has been
ssociated with fatal marrow aplasia and severe graft-
ersus-host disease, and it relies on the availability of
he original donor [3-5].
Imatinib is a potent and selective inhibitor of
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BCR-ABL tyrosine kinase, which is a product of the
himeric gene produced by the Philadelphia (Ph)
hromosome [6,7]. Several studies have demonstrated
hat imatinib therapy induces a major cytogenetic re-
ponse in up to 80% of cases with mild and reversible
oxicities. In the post-SCT settings, it was suggested
hat imatinib should be used as a front-line treatment
or relapsed CML, on the basis of the high response
ate with relative safety [8]. Furthermore, severe graft-
ersus-host disease was observed in a relatively smaller
ortion of relapsed patients [9-13] compared with that
bserved after DLI [3,14].
Considering the high cytogenetic response rate
fter imatinib therapy, a more sensitive monitoring of
inimal residual disease (MRD) under the levels of
he cytogenetic response is needed, particularly in
ost-SCT settings. Real-time quantitative reverse
ranscriptase-polymerase chain reaction (Q-RT-PCR)
orrelates strongly with conventional cytogenetics,
uorescence in situ hybridization, RT-PCR, compet-
tive RT-PCR, and Southern blotting [15-19], and its
tility in MRDmonitoring has been reported by many
uthors [15,20-22]. Because our previous study
howed that the results of Q-RT-PCR were signiﬁ-
antly different according to the positivity of RT-PCR
19], Q-RT-PCR studies of patients who achieve a
omplete cytogenetic response (CCR) after imatinib
herapy may determine the level of molecular re-
ponse, which correlates with a low risk of disease
rogression.
To our knowledge, none of the studies has ad-
ressed the important question of how to select pa-
ients who are unlikely to achieve molecular remission
MR) after a therapy with standard-dose imatinib for
ost-SCT CML relapse and therefore might be ad-
ised to consider alternative therapies. To answer this
uestion, MRD was examined after imatinib therapy
o determine whether it was possible to predict which
atients will eventually achieve an MR by monitoring
heir early trends in the BCR-ABL/ABL ratio at 1, 3,
nd 6 months.
ATIENTS AND METHODS
atients
Adults with Ph-positive or BCR-ABL–positive
ML who had relapsed after a transplantation were
nrolled in this study. The eligibility criteria included
isease status with cytogenetic or hematologic evi-
ence of a relapse and treatment with standard-dose
matinib for at least 1 month. Written, informed con-
ent was received from each patient before enrollment
n this study.
reatment with Imatinib
Imatinib was started at an oral dose of 400 mg/d
or cytogenetic relapse or CP CML and 600 mg/d for
B&MTccelerated phase or blast crisis CML, and the doses
ere adjusted according to the previously published
uidelines for pretransplantation CML [10,23]. The
reatment was continued until the disease was consid-
red unresponsive (no hematologic response after at
east 4 weeks or no cytogenetic response after at least
months of treatment) to imatinib, until the patient
ied, until there was a change to another treatment
including a dose escalation of imatinib), or until the
ppearance of unacceptable adverse events that did
ot respond to dose modiﬁcation.
esponse Analysis
Every 3 months or more frequently, the responses
o imatinib were analyzed from the bone marrow
amples by using conventional cytogenetics, nested
T-PCR, and Q-RT-PCR assays in all cases. The
ytogenetic responses, which were analyzed with the
tandard Giemsa banding method with a minimum of
0 metaphases examined each time, were categorized
s being complete (no Ph-positive metaphases), partial
1%-35% Ph-positive metaphases), minor (36%-65%
h-positive metaphases), minimal (66%-95% Ph-pos-
tive metaphases), and no response (95% Ph-positive
etaphases). MR was deﬁned as the absence of BCR-
BL transcripts in nested RT-PCR and Q-RT-PCR,
s well as full donor chimerism.
CR Assays
The nested RT-PCR and Q-RT-PCR were per-
ormed as previously described [19,24]. Brieﬂy, the
otal RNA was extracted by using an RNAqueous Kit
Ambion, Austin, TX). Reverse transcription was per-
ormed with 1 g of RNA, and samples with less than
g of RNA were discarded. The 2-step nested pro-
edure in triplicate was used for the nested RT-PCR
mpliﬁcation (sensitivity, 106), and Q-RT-PCR was
erformed in triplicate by using iCycler software 2.1
Bio-Rad, Hercules, CA) under the standard condi-
ions (95°C for 10 minutes, 50 cycles at 95°C for 15
econds, and 60°C for 1 minute). The plasmid stan-
ard titrations with the deﬁned copy numbers for the
CR-ABL and the reference ABL were analyzed si-
ultaneously with the patient samples, and the 50-L
CR reaction mixture contained 5 L of 10 PCR
uffer, 4.5 mmol/L MgCl2, 0.2 mmol/L deoxynucleo-
ide triphosphate, 0.2 mol/L primers, 140 nmol/L
aqMan probe (Tibmolbiol, Berlin, Germany), 1.25
of AmpliTaq Gold (PE Applied Biosystems, Foster
ity, CA) DNA polymerase, and 4 L of target com-
lementary DNA. The quantity of the BCR-ABL
ranscript was normalized to the ABL expression level
sensitivity, 105).719
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7himerism Analysis
Chimerism analysis using a multiplex short tan-
em repeat was performed with the AmpF/STR Iden-
iﬁler PCR Ampliﬁcation Kit (PE Applied Biosystems,
oster City, CA), and the fragments were analyzed on
n ABI Prism 310 Genetic Analyzer (PE Applied Bio-
ystems), as previously described [25].
tatistical Analysis
The end points for response analysis were calcu-
ated on the basis of the date of the last bone marrow
xamination and for the survival on the date of the last
ollow-up. The outcome probabilities, such as CCR,
R, and overall survival, were calculated with the
aplan-Meier method; the comparison was made by
sing the log-rank test. The Mann-Whitney test was
sed to compare the normalized BCR-ABL transcripts
evels between appropriate groups. All quoted P values
ere 2 sided, and a P value .05 was considered
igniﬁcant.
ESULTS
atients
A total of 23 patients with a median age of 33
ears, in whom CML had relapsed at a median of 13.6
onths after the SCT, were enrolled in this study
Table 1). The duration of imatinib therapy was a
edian of 399 days (range, 35-817 days). Before ima-
inib therapy, immunomodulatory treatment such as
mmunosuppressant withdrawal, DLI, or interferon
as given to 19 of 23 patients, and the median interval
rom salvage treatment to imatinib therapy was 6.5
onths (range, 3.1-59.3 months). Among them, 16
atients had refractory disease (deﬁned as no hemato-
ogic response at 3 months or no cytogenetic response
t 6 months after treatment) to these treatments: dis-
ase progression at a median of 6.7 months after
arious treatments (n  10); no cytogenetic responses
t 6.5 months after immunosuppressant withdrawal (n
2); or no hematologic responses at a median of 7.7
onths after DLI and/or interferon (n  3) or at 4.4
onths after immunosuppressant withdrawal (n  1).
he disease phase at the initiation of imatinib therapy
as a cytogenetic relapse in 3 patients, CP in 6 pa-
ients, accelerated phase in 9 patients (all classiﬁed
nly because of the presence of acquired clonal aber-
ations), and blast crisis in 5 patients.
ytogenetic Response
CCR was observed in 19 (83%) of the 23 patients.
mong the remaining 4 patients, 1 patient achieved a
artial cytogenetic response, and the others did not
chieve any cytogenetic response. The time to CCR
as a median of 97 days (range, 27-285 days) after the F
20nitiation of imatinib therapy. According to the disease
hase at the initiation of imatinib therapy, the CCR
ate was 100% (3/3) in cytogenetic relapse, 83% (5/6)
n CP, 89% (8/9) in accelerated phase, and 60% (3/5)
n blast crisis. The probability of overall survival after
matinib therapy was signiﬁcantly different between
hose who had experienced CCR (83%) and those
ho had not (0%) (P  .002).
olecular Response among the Patients Achieving
CR
Nineteen patients with CCR were divided into 2
roups (MR group versus CCR group) according to
he best response to imatinib therapy and the Q-RT-
CR data were compared between the 2 groups.
leven (58%) patients were classiﬁed as being in the
R group, in whom an MR was achieved at a median
f 279 days (range, 90-559 days) and persisted for a
edian of 190 days (range, 30-370 days), and none of
he MR patients lost their response until the time of
ata analyses. Of 8 patients in the CCR group, 6
atients remained in continuous CCR for a median of
56 days (range, 144-700 days), whereas 2 patients lost
heir CCR after 52 and 281 days. The overall survival
robability after imatinib therapy was signiﬁcantly
igher in the MR group (100%) than in the CCR
roup (60%) (P  .03; Figure 1).
inetics of BCR-ABL Transcript Levels among the
atients Achieving CCR
Quantitative monitoring by Q-RT-PCR showed a
apid decline in the normalized BCR-ABL transcripts
uring 3 months of imatinib therapy in both the MR
nd CCR groups (Figure 2). After then, the median
CR-ABL/ABL ratio progressively declined in the
R group, whereas it slowly increased after 6 months
n the CCR group. The BCR-ABL/ABL ratios were
ot signiﬁcantly different between groups at 1 month
median, 0.03 for MR and 0.03 for non-MR) and 3
onths (median, 0.00004 for the MR group and
.00099 for the CCR group). However, they were
igniﬁcantly different after 6 months of therapy (me-
ian, 0.0000012 for the MR group and 0.00022 for the
CR group; P  .003; Table 2).
rediction of MR with BCR-ABL Transcript Levels
mong the Patients Achieving CCR
No signiﬁcant levels were identiﬁed to be useful
or discriminating the subsequent MR when using the
-RT-PCR results at 1 month or 3 months. When
he Q-RT-PCR results at 6 months were analyzed in
0 patients who remained in CCR until 6 months, the
robability of a subsequent MR was signiﬁcantly
igher in patients with BCR-ABL/ABL ratios
0.0001 (100% versus 33% for 0.0001; P  .006;
igure 3a). Because there were signiﬁcant differences
Table 1. Characteristics and the Responses to Imatinib Therapy of the Enrolled Patients
Case
Age/
Sex SCT Type
Disease
Status at
SCT
Relapse Status
(Months after SCT)
Salvage Treatment
(Months after Relapse)
Status at IMTx
(Months after
Relapse)
Best Response to IMTx
(Duration; d) Survival (d)* Log (3m/6m)
1 45/F Mismatched-related AP CyRel (11.6) IS-W (0.2)† CyRel (6.7) MR (190) Alive, 370 >3
2 35/M Matched-related CP CyRel (18.0) None CyRel (4.6) MR (126) Alive, 216 >3
3 31/F Matched-related CP CP (56.9) None CP (0.6) MR (139) Alive, 418 1.4
4 31/M Matched-unrelated CP CP (28.2) IS-W (1.7) CP (2.2) MR (293) Alive, 643 0.6
5 32/F Matched-related CP CP (33.8) DLI (0.8)† CP (5.2) MR (370) Alive, 817 1.56
6 33/F Matched-related AP CP (60.7) DLI  IFN (0.2)† CP (7.9) MR (30) Alive, 399 2.1
7 45/M Matched-related AP AP (4.9) DLI  INF (1.6) AP-CE (4.0) MR (327) Alive, 640 1.5
8 46/F Matched-related CP CyRel (18.9) DLI (1.7)† AP-CE (9.1) MR (63) Alive, 622 2.0
9 22/M Matched-related CP CyRel (9.3) DLI  INF (0.5)† AP-CE (15.0) MR (209) Alive, 404 >3
10 30/F Matched-unrelated CP CyRel (23.1) IS-W (0.6)† AP-CE (6.6) MR (299) Alive, 397 >3
11 36/F Matched-related CP CyRel (7.6) IS-W (0.8)† AP-CE (5.0) MR (70) Alive, 250 >3
12 32/M Matched-related CP CyRel (11.5) IS-W (0.6)† CyRel (7.1) CCR (242) Alive, 332 0.3
13 56/M Matched-related CP CP (18.8) DLI  IFN (5.1)† CP (8.2) CCR (700) Alive, 800 0.1
14 33/M Matched-unrelated CP CyRel (3.6) IS-W (0.3)† AP-CE (3.5) CCR (52) Died of relapsed disease,
79
NA
15 28/M Matched-related CP CyRel (11.0) DLI  IFN (0.9)† AP-CE (10.5) CCR (306) Alive, 411 1.4
16 30/F Syngeneic CP CyRel (5.4) DLI  IFN (0.3)† AP-CE (10.0) CCR (486)‡ Alive, 583 0.5
17 43/M Matched-related CP CyRel (67.3) DLI (1.5) BC (2.0) CCR (281) Died of relapsed disease,
525
0.9
18 55/M Autologous CP CP (15.8) Chemotherapy (5.1)† BC (28.1) CCR (406) Alive, 550 0.66
19 22/F Matched-related BC BC (6.3) None BC (0.1) CCR (144) Died of relapsed disease,
211
2.8
20 45/F Matched-related BC CyRel (13.6) DLI (1.0)† BC (4.2) PCR Died of relapsed disease,
72
NA
21 37/M Matched-related CP CP (3.0) IFN (1.1)† CP (60.4) NR Died of refractory
disease, 474
0.58
22 36/M Matched-unrelated CP CyRel (13.0) IS-W (0.6)† AP-CE (4.2) NR Alive, 272 0.60
23 19/F Matched-related CP CP (21.2) None BC (0.2) NR Died of refractory
disease, 259
NA
SCT indicates stem cell transplantation; IMTx, imatinib therapy; CP, chronic phase; AP, accelerated phase; AP-CE, AP with clonal evolution alone, BC, blast crisis; Rel, relapse; CyRel, cytogenetic
relapse; IFN, interferon; DLI, donor lymphocyte infusion; IS-W, immunosuppressant withdrawal; CCR, complete cytogenetic response; PCR, partial cytogenetic response; NR, no response; NA,
not available.
*Days after the initiation of imatinib therapy.
†Refractory to salvage treatment, deﬁned as no hematologic response at 3 months or no cytogenetic response at 6 months while receiving immunomodulatory treatment.
‡MR induced after 4 months of high-dose imatinib therapy.
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7n the BCR-ABL/ABL ratio between the 2 groups
uring third and sixth months, the prediction of an
R was evaluated with a log-reduction during that
ime in the 15 patients remaining in CCR until 3
onths. A signiﬁcant difference in the probability of a
ubsequent MR was observed at the log-reduction
evel of 1.0 (log-reduction 1.0, 100%; 1.0, 17%; P
.003; Figure 3b).
ISCUSSION
This study monitored the BCR-ABL/ABL ratio
fter imatinib therapy in patients with relapsed CML
fter transplantation. The patients, who at some point
ad an undetectable BCR-ABL, were identiﬁed to be
ssociated with an improved survival. This study also
howed that normalized BCR-ABL transcript levels in
atients who eventually achieved an MR signiﬁcantly
igure 1. Probability of overall survival according to the best
esponse after imatinib therapy in patients achieving a complete
ytogenetic response.
igure 2. Kinetics of the normalized BCR-ABL transcript levels i
esponse (b) as a best response to imatinib therapy.
22ecrease within the ﬁrst 6 months of imatinib therapy;
herefore, the early monitoring of BCR-ABL by Q-
T-PCR may indicate a subsequent MR.
Cytogenetic assays continue to be regarded as the
tandard method for assessing the response to various
herapies for CML. Obtaining a major response or a
CR has been associated with excellent long-term
urvival after interferon treatment [26]. Therefore, the
ytogenetic response to imatinib therapy may provide
seful prognostic information. A signiﬁcant number
f patients achieve a CCR on imatinib therapy. Ap-
roximately 75% of newly diagnosed CP CML pa-
ients who were initially treated with imatinib and
pproximately 40% of late CP patients who were
reated with imatinib after interferon therapy failure
chieved a CCR [27,28]. In imatinib therapy for post-
ransplantation relapse, limited series with a small
umber of cases have been analyzed for cytogenetic
esponse. The results of the 8 literature reviews
howed that 51 (45%) of 114 evaluable patients
chieved a CCR [13]. Our recent experience with 13
atients with CP with or without clonal aberrations
nts achieving a molecular remission (a) or a complete cytogenetic
able 2. Comparison of the Median BCR-ABL/ABL Ratio at 1, 3,
nd 6 Months According to the Best Responses in Patients Achieving a
omplete Cytogenetic Response
Variable
Best Response
P
Value*MR CCR
11 8
edian duration of
IM-Tx, d (range) 404 (216-817) 450 (35-800)
CR-ABL/ABL ratio
Before transplantation 0.25 0.54 .74
Month 1 0.03 0.03 .95
Month 3 0.0004 0.00099 .62
Month 6 0.0000012 0.00033 .003
R indicates molecular remission; CCR, complete cytogenetic
remission, IM-Tx, imatinib therapy.
Mann-Whitney test.n patie
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Bhowed the CCR rate to be90% [8]. In this study, it
as observed that 78% of the enrolled patients
chieved a CCR, but the reason for the higher CCR
ate in our study is not obvious. Among the various
ossible factors, such as disease or chimeric status and
ime from transplantation to relapse, partial inﬂuences
f prior salvage treatment should be considered, al-
hough most enrolled patients had diseases that pro-
ressed or did not respond after long-term observa-
ion. Although this study was conducted on a small
roup of patients, we suggest that achieving CCR is an
mportant prognostic factor for survival.
Regarding the high CCR rate after imatinib ther-
py, the next concern focuses on the response under
he cytogenetic level. It is known that achievement of
R after DLI is highly predictive of better survival in
atients with relapsed CML [4]. Whether the achieve-
ent of MR on imatinib therapy also correlates with
he long-term outcome is not yet known. Although
eterogeneity in the molecular response was found in
he complete cytogenetic responders after interferon
r imatinib, low levels of MRD were associated with
ontinuous remission [29-32]. This study showed that
he probability of survival for patients who achieved
n MR was signiﬁcantly better than for those who did
ot. Whether imatinib can replace DLI depends on
he rate and duration of MR, which should be revealed
n larger series. To deﬁne the role of imatinib in
omparison with DLI for post-SCT CML relapse,
tudies on how long imatinib therapy should be con-
inued in patients achieving MR should also be per-
ormed.
The fact that approximately 40% of patients who
chieved a CCR in this study did not achieve an MR,
ven with the continuation of imatinib therapy, un-
erlies the need for a more sensitive method for pre-
icting an MR and for recognizing the early warning
igns of imatinib resistance. Q-RT-PCR has been
igure 3. Probability of molecular remission according to the BC
CR-ABL transcript levels between 3 and 6 months (b).sed in monitoring BCR-ABL expression after ima- l
B&MTinib therapy [11,12,31,33,34]. Recent reports suggest
hat a normalized BCR-ABL transcript level with Q-
T-PCR correlates with the contemporary or subse-
uent marrow cytogenetic response [35-37]. Similarly,
good correlation between the BCR-ABL transcript
evels and the cytogenetic response was observed in
his study (data not shown). In all patients achieving a
CR, a rapid decline in the BCR-ABL/ABL ratio was
bserved during the initial 3 months of imatinib ther-
py in both groups. However, the decrease in the
CR-ABL/ABL ratio during the next 3 months was
igniﬁcantly greater in the patients who were destined
o achieve an MR. This ﬁnding suggests that poor
esponders can be predicted and approached with
ther therapeutic options by early molecular monitor-
ng with Q-RT-PCR. Alternatively, hazardous thera-
ies can be avoided for the patients who are likely to
cquire an MR and subsequent long-term disease con-
rol.
Extremely poor end results in blast crisis were
bserved in this study; 4 of 5 patients died of refrac-
ory or relapsed disease after a transient response.
his ﬁnding suggests that more potent therapies
hould be considered. In addition, therapeutic strate-
ies should be established for patients who do not
chieve an MR. Possible approaches could be a dose
scalation of imatinib or combinations of imatinib
ith DLI, low-dose cytarabine, or interferon. Al-
hough high-dose imatinib led to more favorable out-
omes and was reported to be beneﬁcial for overcom-
ng the resistance to standard-dose treatment [38,39],
t is not known whether there is dose-dependent re-
ponsiveness in patients with relapsed CML. How-
ver, one patient (case 16), in whom imatinib was
ncreased to 800 mg/d after the CCR had continued
or more than 12 months of standard-dose imatinib,
chieved an MR after 4 months of high-dose therapy.
his ﬁnding illustrates the possible role of dose esca-
transcript levels at 6 months (a) and to the log-reduction of theR-ABLation even in a posttransplantation setting.
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7Although standardization of the Q-RT-PCR
ethod will be needed in the near future, it is believed
hat quantitative determination of residual disease
ith Q-RT-PCR is a reliable and sensitive method for
onitoring the MRD. It was also shown that the early
rend in the BCR-ABL/ABL ratio might be clinically
seful for the early identiﬁcation of patients who are
estined to achieve an MR on imatinib.
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